Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.

Abstract

We conclude that carboplatin with WBH is well tolerated even at conventional carboplatin doses. Clinical results are consistent with preclinical predictions of an increased therapeutic index for this combination, which encourages future clinical studies.